With a single discovery, CureVac opened the world up to the potential of mRNA to treat diseases and create vaccines. Officially founded in 2000, CureVac is the world’s first company to …

CureVac reports positive interim Phase 1 data for its COVID-19 vaccine candidate, CVnCoV: Data show balanced immune response with strong induction of binding and neutralizing antibodies …

CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology …

Through our proprietary mRNA technology we are able to directly give the body the information it needs to fight disease. Driven by passion for patients, we seek life-altering results for …

CureVac ist ein globales biopharmazeutisches Unternehmen mit über 20 Jahren Erfahrung in der Entwicklung der mRNA-Technologie für medizinische Zwecke.

2022年8月18日 · CV0501 is CureVac’s first COVID-19 vaccine candidate applying chemically modified mRNA from the COVID-19 vaccine program developed in collaboration with GSK. It …

2023年8月1日 · CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid …

2024年1月5日 · CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid …

Our path towards a new class of safe and effective therapeutics started 20 years ago, with the unexpected discovery by CureVac founder Ingmar Hoerr of the therapeutic potential of …

“I am very excited to be part of CureVac and to help develop new therapeutic options against severe diseases. mRNA technology has the potential to revolutionize medicine and to be …